CD3
Cluster of differentiation 3
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex.
All Product Categories
-
CD3 관련 제품 (108)
관련 제품 (108)
-
Antibodies (20)
-
ISB2001
0 ImagesCat. No.: HY-P991490Purity: 99.17%ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.
-
Avitotamig
0 ImagesCat. No.: HY-P990903CAS No.: 2577961-36-3Synonyms: YMS-5AHY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody.
-
Etevritamab
0 ImagesCat. No.: HY-P99948CAS No.: 2329692-74-0Synonyms: AMG-596Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma.
-
Anti-Mouse CD3ε Antibody (KT3)
0 ImagesCat. No.: HY-P990272Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε. Anti-Mouse CD3ε Antibody (KT3) increases thymocytes proliferation. Anti-Mouse CD3ε Antibody (KT3) can be used for the research of immunology.
-
Emirodatamab
0 ImagesSynonyms: AMG-427Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases.
-
Nebratamig
0 ImagesCat. No.: HY-P991209CAS No.: 2694723-68-5Synonyms: GNC-035
-
Zubotamig
0 ImagesCat. No.: HY-P990953CAS No.: 2640279-10-1Synonyms: Gen1047Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer).
-
Emfizatamab
0 ImagesCat. No.: HY-P99914CAS No.: 2559704-23-1Synonyms: GNC-038Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.
-
Nelvutamig
0 ImagesCat. No.: HY-P991706CAS No.: 3029433-56-2Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Human immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3).
-
Besufetamig
0 ImagesSynonyms: ONO-4685Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.
-
Tidutamab
0 ImagesCat. No.: HY-P99562CAS No.: 2148354-90-7Synonyms: XmAb-18087Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).
-
Trevotamig
0 ImagesCat. No.: HY-P991034CAS No.: 2920215-79-6HY-P991034 is an EPCAM/CD3E-targeting H-γ1_L-κ-scFvhl dimer type bispecific antibody.
-
Amtabafusp alfa
0 ImagesSynonyms: GS-8588Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection.
-
UR-1505
0 ImagesUR-1505 is a nuclear factor of activated T cells (NF-AT) inhibitor. UR-1505 can suppress CD3/CD28 induced T cell proliferation, increase p27KIP levels, and induce G1/S cell cycle arrest. UR-1505 can also inhibit the production of IL-5 and IFN-γ in activated T cells. UR-1505 has immunomodulatory properties and can be used in the study of atopic dermatitis.
-
Dafsolimab
0 ImagesCat. No.: HY-P99837CAS No.: 2367001-71-4Synonyms: SPV-T3a
-
Anti-CD3 Antibody (UCHT-1)
0 ImagesCat. No.: HY-P991842Anti-CD3 Antibody (UCHT-1) is an antibody targeting CD3. Anti-CD3 Antibody (UCHT-1) activates the phospholipase C and phosphatidylinositol 3-kinase (PI3K) signaling pathways, elevates intracellular calcium levels, regulates the T3 epitope, and triggers T lymphocyte proliferation. Anti-CD3 Antibody (UCHT-1) also inhibits lymphocyte proliferation, abolishes IL-2 production, and blocks the expression of IL-2 receptors. Anti-CD3 Antibody (UCHT-1) is applicable to research related to graft-versus-host disease, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia.
-
Emaretamig
0 ImagesCat. No.: HY-P991681CAS No.: 3051701-97-1Synonyms: ASP-2138
-
Obertamig
0 ImagesCat. No.: HY-P990714CAS No.: 2750126-32-8Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv).
-
SAR-442257
0 ImagesCat. No.: HY-P991183Purity: ≥99.0%SAR-442257 is a trispecific T-cell engager and monoclonal antibody that binds to CD38, CD3 and CD28. SAR-442257 can target and bind to CD3 and CD28 on T cells, as well as CD38 expressed on tumor cells. SAR-442257 mediates T-cell activation, enhances T-cell activity, induces T-cell degranulation, and drives cytotoxicity against multiple myeloma cells. SAR-442257 functions via CD38 expression, and its in vitro activity correlates with CD38 expression on the surface of multiple myeloma cells. SAR-442257 can be used in studies related to multiple myeloma and relapsed/refractory multiple myeloma.
